[Significance of setting standards and guidelines for management of patients with hyperlipidemia].
Kotake
H
H
Tohoku CC Health Care Division, Japan Tobacco Inc.
Oikawa
S
S
D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000628:therapy*; D015228:Hypertriglyceridemia / Q000175:diagnosis / Q000628:therapy; D007009:Hypolipoproteinemias / Q000175:diagnosis / Q000628:therapy; D008019:Life Style; D017410:Practice Guidelines as Topic / Q000592:standards; D012015:Reference Standards
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors